GlassScriptPhysician profile
Mary Victoria Wright
NPI 1679188767
$1,348.69
in general payments reported to CMS, 2019-2025
18 companies · $544 in 2025
The $544 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.40 · 2023: $112 · 2024: $679 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $505.12 | 2024-2025 | Omnipod |
| Medtronic, INC. | $179.51 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $91.59 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $88.78 | 2024-2025 | Mounjaro, Zepbound |
| Beta Bionics, INC. | $73.55 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $63.75 | 2024 | |
| Amgen INC. | $56.62 | 2023-2024 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $56.58 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $45.66 | 2024-2025 | Ozempic |
| Hollister Incorporated | $32.68 | 2025 | Premier, New Image |
| Ascensia Diabetes Care US INC. | $23.06 | 2025 | |
| Astellas Pharma US INC | $22.83 | 2024 | Veozah |
| Tolmar, INC. | $20.58 | 2025 | Jatenzo |
| Recordati_rare_diseases_inc. | $19.68 | 2023 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $19.08 | 2024 | Crysvita |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $18.55 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $16.67 | 2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.